Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
NanoViricides, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
NNVC
NYSE American
2836
www.nanoviricides.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for NanoViricides, Inc.
NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape
- Feb 11th, 2025 11:30 am
NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025
- Jan 29th, 2025 11:30 am
NanoViricides Engages CRO for Phase II Clinical Trial
- Jan 27th, 2025 11:30 am
NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025
- Jan 13th, 2025 11:30 am
Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals
- Jan 8th, 2025 11:30 am
NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape
- Dec 23rd, 2024 11:30 am
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025
- Nov 27th, 2024 12:00 pm
NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID
- Nov 15th, 2024 11:30 am
NanoViricides: Fiscal Q1 Earnings Snapshot
- Nov 15th, 2024 12:20 am
NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am
- Nov 4th, 2024 5:00 am
NanoViricides President Dr. Diwan to Present at the PODD Conference
- Oct 22nd, 2024 10:30 am
NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology
- Oct 15th, 2024 10:30 am
NanoViricides Inc. (NNVC): Best Nanotech Penny Stock to Buy
- Oct 14th, 2024 5:30 pm
NanoViricides to Present at the Global AMR Summit 2024 Tomorrow
- Oct 8th, 2024 10:30 am
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID
- Sep 30th, 2024 10:30 am
NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including “Trojan Horse” Drugs
- Sep 26th, 2024 10:30 am
MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX
- Aug 26th, 2024 11:30 am
NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 - A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections
- Aug 19th, 2024 10:30 am
NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as Antibiotics
- Aug 8th, 2024 10:30 am
Can Nanotechnology offer Better Solutions for COVID, RSV and other Viruses?
- Aug 2nd, 2024 11:00 am
Scroll